Recent developments for Liminatus Pharma include a $4 million offering of shares and warrants, a strategic review of digital asset strategies for treasury management, and ongoing Nasdaq compliance issues related to market value and bid price rules.

• In February 2026, Liminatus Pharma priced a $4 million public offering of common stock, pre-funded warrants, and common stock purchase warrants with specific exercise terms and a placement agency agreement with Maxim Group LLC [N1][S1].
• In July 2025, the company initiated a strategic review of regulated digital asset strategies for treasury management [N4].
• The company has been notified by Nasdaq of non-compliance with listing rules related to minimum market value of listed securities, minimum market value of publicly held shares, and minimum bid price, with compliance periods extending into mid-2026 [S1].

Potential value could arise if the company successfully executes its strategic initiatives, including the review and possible implementation of regulated digital asset strategies for treasury management, and regains Nasdaq compliance through capital raising efforts. However, these remain unconfirmed and lack detailed disclosure.

The company faces significant risks from its poor liquidity position, substantial net losses, and ongoing Nasdaq listing compliance issues. Failure to regain compliance could lead to delisting, and the lack of disclosed revenue or business model clarity increases uncertainty about its operational viability.

There is insufficient public information to assess Liminatus Pharma's competitive advantages or moat. The company’s business model, product offerings, and market positioning are not clearly disclosed in available filings or news sources.

• Liquidity Risk: The company reported a current ratio of 0.05 as of December 31, 2025, indicating a severe liquidity shortfall relative to current liabilities [S1].
• Nasdaq Listing Compliance Risk: Liminatus Pharma has received multiple Nasdaq deficiency notices for failure to meet minimum market value and bid price requirements, with compliance deadlines in 2026 [S1].
• Operational and Business Model Uncertainty: There is limited public disclosure about the company’s core business operations, products, or revenue streams, increasing uncertainty about its ability to generate sustainable income.

• Liminatus Pharma, Inc. is a publicly traded company on Nasdaq under the ticker LIMN [S1].
• The company is classified as an emerging growth company [S1].
• As of December 31, 2025, the company reported current assets of $500,574 and current liabilities of $10,298,241, resulting in a current ratio of 0.05, indicating significant liquidity constraints [S1].
• The company reported a net loss of $10,206,517 for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.43 [S1].
• Liminatus Pharma has been non-compliant with Nasdaq listing rules related to minimum market value of listed securities, minimum market value of publicly held shares, and minimum bid price, with compliance periods extending into mid-2026 [S1].
• The company initiated a strategic review of regulated digital asset strategies for treasury management in July 2025 [N4].
• In February 2026, Liminatus Pharma priced a $4 million offering of common stock and warrants, including pre-funded warrants and common stock purchase warrants, with specific terms and a placement agency agreement involving Maxim Group LLC [N1, S1].
• In February 2026, the company entered into a settlement and release agreement involving the issuance of 4 million shares in exchange for cancellation of warrants and dismissal of related litigation with Clear Street LLC [S1].